Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT06176040 Recruiting - Atopic Dermatitis Clinical Trials

A Study of TAVO101 in Atopic Dermatitis Patients

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with severe AD.

NCT ID: NCT06175143 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.

Start date: December 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase Ib clinical trial evaluating the safety tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of GR2002 Injection in patients with moderate to severe atopic dermatitis. The dosing period was 12 weeks and followed up to 20 weeks.

NCT ID: NCT06174493 Not yet recruiting - Atopic Dermatitis Clinical Trials

Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials

Start date: January 2025
Phase:
Study type: Observational

Clinical trials, specifically focused on atopic dermatitis, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.

NCT ID: NCT06173284 Recruiting - Dermatitis, Atopic Clinical Trials

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Start date: January 22, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to evaluate the efficacy of 611 in Chinese adults with moderate to severe atopic dermatitis.

NCT ID: NCT06170983 Not yet recruiting - Skin Infection Clinical Trials

Skin Inflammation and PK of Azithromycin

AZI_IMQ_LPS
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study will investigate the tissue distribution of azithromycin in healthy, artificially inflamed and actually infected tissue of humans.

NCT ID: NCT06169527 Recruiting - Atopic Dermatitis Clinical Trials

A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab

DUPILAB
Start date: November 28, 2023
Phase:
Study type: Observational

This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.

NCT ID: NCT06162507 Not yet recruiting - Atopic Dermatitis Clinical Trials

Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Start date: March 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.

NCT ID: NCT06158490 Not yet recruiting - Clinical trials for Moderate-to-severe Atopic Dermatitis

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Start date: December 10, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: - The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. - The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: - Be treated with either a low-dose or high-dose of JYP0061. - Undergo efficacy and safety evaluations as stipulated in the trial protocol.

NCT ID: NCT06158347 Recruiting - Breast Cancer Clinical Trials

Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer

HBOT
Start date: November 6, 2023
Phase: N/A
Study type: Interventional

This study aimed to evaluate reducing the incidence of radiation dermatitis by assigning hyperbaric oxygen therapy to patients with localized breast cancer.

NCT ID: NCT06144424 Active, not recruiting - Atopic Dermatitis Clinical Trials

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

EASE
Start date: October 25, 2023
Phase: Phase 2
Study type: Interventional

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis